Sol-gel Technologies Ltd.

Biotechnology • Healthcare • Ness Ziona, Israel • SLGL (NCM)

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

Stock Performance (90 Days)

Data through Dec 23, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Easily Afford To Drive Business Growth - Yahoo Finance

Yahoo Finance • Dec 29

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Buys $944,649.03 in Stock - MarketBeat

MarketBeat • Jan 1

Major Stakeholder Makes Bold New Move in Sol-Gel Technologies - TipRanks

TipRanks • Jan 1

HC Wainwright & Co. Reiterates Sol-Gel Technologies (SLGL) Buy Recommendation - Nasdaq

Nasdaq • Dec 22

Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases $361,500.30 in Stock - MarketBeat

MarketBeat • Jan 1

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Sol-Gel Technologies Ltd. had layoffs?

No layoff events have been recorded for Sol-Gel Technologies Ltd. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Sol-Gel Technologies Ltd. have?

Sol-Gel Technologies Ltd. has approximately 34 employees.

What industry is Sol-Gel Technologies Ltd. in?

Sol-Gel Technologies Ltd. operates in the Biotechnology industry, within the Healthcare sector.

Is Sol-Gel Technologies Ltd. a publicly traded company?

Yes, Sol-Gel Technologies Ltd. is publicly traded under the ticker symbol SLGL on the NCM. The company has a market capitalization of approximately $0.12 billion.

Where is Sol-Gel Technologies Ltd. headquartered?

Sol-Gel Technologies Ltd. is headquartered in Ness Ziona, Israel.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.